Vanda Pharmaceuticals Inc.
VNDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001347178
In the last 90 days, Vanda Pharmaceuticals Inc. insiders filed 1 open-market purchase and 0 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $304.1M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $246.7M
- Insider buysLast 90 days, $38.1K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +3 vs. previous quarter
- 172
- 13F valueReported value at the end of Q2 2026
- $304.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $216.1M
- +8.7% year over year
- Net income, FY2025
- -$220.5M
- No comparable prior period
- Free cash flow, FY2025
- -$110.4M
- No comparable prior period
- Revenue, Q3 FY2026
- $69.8M
- +24.1% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $220.5M (102.0% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 7.62M
- Shares sold short
- Change
- −686.1K
- −8.3% vs. previous
- Days to cover
- 5.93
- At average daily volume
Superinvestors holding VNDA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding VNDA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Vanda Pharmaceuticals Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 5, 2026 (view filing)4:16 PM ET | Nov 3-5 | 2 days | Duncan Charles CliffDirector | PPurchase | +10.0K | $3.81 | +$38.1K | +10.1%108.7K after | 3 lots |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Moran Kevin PatrickSVP, CFO & Treasurer | SSale | −42.4K | $8.27 | −$351.0K | −9.4%411.4K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Wijkstrom JoakimSVP, Chief Marketing Officer | SSale | −30.8K | $8.27 | −$254.7K | −8.5%333.5K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Williams TimothySVP & General Counsel | SSale | −42.4K | $8.27 | −$350.9K | −10.1%377.4K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Birznieks GuntherSVP, Business Development | SSale | −42.4K | $8.27 | −$350.9K | −7.9%494.2K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Polymeropoulos Mihael HristosPresident and CEO | SSale | −156.2K | $8.17 | −$1.28M | −5.5%2.70M after | |
| Feb 24, 2026 (view filing) | Feb 23 | 1 day | Honore TageDirector | SSale | −30.0K | $8.03 | −$240.9K | −24.3%93.5K after | |
| Aug 8, 2025 (view filing) | Aug 7 | 1 day | Polymeropoulos Mihael HristosPresident and CEO | PPurchase | +10.0K | $4.15 | +$41.5K | +0.4%2.34M after | |
| Jun 16, 2025 (view filing) | Jun 13 | 3 days | Mitchell Stephen RayDirector | SSale | −7.00K | $4.59 | −$32.1K | −6.7%97.1K after | |
| May 21, 2025 (view filing) | May 21 | Same day | Polymeropoulos Mihael HristosPresident and CEO | PPurchase | +10.0K | $4.40 | +$44.0K | +0.4%2.33M after | 2 lots |
Top 10 13F holders, Q2 2026
See all 172 holdersThe largest institutional positions in Vanda Pharmaceuticals Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,653,737 | $46.8M | 0.00% | +377,749+5.2% | Added |
| State Street Corp | 3,516,405 | $21.5M | 0.00% | +500,843+16.6% | Added |
| AQR Capital Management LLC | 3,497,695 | $21.4M | 0.01% | +1,894,119+118.1% | Added |
| Renaissance Technologies LLC | 3,441,361 | $21.1M | 0.03% | −318,198−8.5% | Reduced |
| Vanguard Capital Management LLC | 2,524,040 | $15.4M | 0.00% | +42,549+1.7% | Added |
| AIGH Capital Management LLC | 2,044,169 | $12.5M | 1.13% | −705,831−25.7% | Reduced |
| Acadian Asset Management LLC | 1,918,063 | $11.7M | 0.01% | +122,471+6.8% | Added |
| Dimensional Fund Advisors LP | 1,727,349 | $10.6M | 0.00% | −44,244−2.5% | Reduced |
| Millennium Management LLC | 1,602,813 | $9.81M | 0.01% | −278,188−14.8% | Reduced |
| Geode Capital Management, LLC | 1,483,787 | $9.08M | 0.00% | +40,822+2.8% | Added |
Holders of 5% or more of VNDA
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Vanda Pharmaceuticals Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 8.10%4.70M shares | −7.50 ppfrom 15.60% | Feb 5, 20252 filings | Feb 7, 2025 | SEC |
| Millennium Management LLC | 13G/A | 7.00%4.26M shares | +1.40 ppfrom 5.60% | Jul 1, 20254 filings | Oct 9, 2026 | SEC |
| BlackRock Portfolio Management LLC | 13G | 5.90%3.59M shares | +1.70 ppfrom 4.20% | Apr 15, 20254 filings | Oct 27, 2026 | SEC |
| AQR Capital Management LLC | 13G | 5.82%3.50M shares | New | Aug 13, 20261 filing | Aug 13, 2026 | SEC |
| State Street Corp | 13G | 5.00%3.01M shares | −0.10 ppfrom 5.10% | Feb 11, 20216 filings | Nov 10, 2026 | SEC |